At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 21 enrolled
Drug / intervention
Sandostatin LARdrug
Likely dose
Sandostatin LAR 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Metabolic, Cardiovascular and Body Composition Effects of Sandostatin LAR® Therapy of Acromegaly, Effect of Reduction of Serum Insulin-like Growth Factor 1 (IGF-1) Levels Into a New Normative Range
In Brief
A Phase 4 clinical trial evaluating Sandostatin LAR for Acromegaly. Completed, enrolled 21 participants across 1 site.
Detailed Summary
This study aims primarily to determine the effect Insulin-like Growth Factor 1 (IGF-1) normalization into current IGF-I normal ranges with Sandostatin LAR® therapy on biochemical metabolic, cardiovascular and body composition parameters in patients with active acromegaly.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcromegaly
CountriesUnited States
CollaboratorsNovartis
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedAug 2011
Primary CompletionMar 2013
Study CompletionJan 2014
TodayJul 2026
First PostedAug 26, 2011
Enrollment StartOct 1, 2006
Primary CompletionMar 1, 2013
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 14.8 years ago
Interventions
Sandostatin LARdrug
Open label dose escalation of Sandostatin LAR 10 mg, 20 mg, 30 mg, up to 40 mg if necessary.